ISSN: 2345-3346
Autumn 2022
Vol. 10 No. 4 (2022)
SARS-CoV-2 IgG and IgM Analysis in Patients Who Attended a University Hospital During the COVID-19 Epidemic in Iran
Novelty in Biomedicine,
Vol. 10 No. 4 (2022),
,
Page 226-231
https://doi.org/10.22037/nbm.v10i4.38313
Abstract
Background: The world is facing a new coronavirus that causes a respiratory infection called COVID-19.
Therefore, there is an increasing request for antibody tests in recovered individuals since they want to evaluate
their immunity against SARS-CoV-2 reinfection.
Materials and Methods: In our study, we had 1000 blood samples from patients admitted to the Ghiassi Hospital,
Tehran, Iran, or were asked to perform serological SARS-COV-2 IgM and IgG tests by their physicians were
collected. The antibody levels were assessed via the ELISA assay method using S and N antigens during various
waves of the COVID-19 epidemic in Iran.
Results: The highest IgG level (2.77) compared to the average (with 95% confidence) is observed in patients
infected in the third wave, which is confirmed by the ANOVA test. The mean IgM concentration in the second
wave was equal to 0.77 and more than the IgM level in the third wave and the beginning of the fourth wave,
which was confirmed by the ANOVA test.
Conclusion: Detection of SARS-COV-2 IgG, IgM has significant potential for evaluating the severity and
prognosis of COVID-19. In addition, all seroepidemiology data in each community can help Health
Commissions for controlling this pandemic. These data also can be used for epidemiological modeling and
assessing the prevalence of COVID-19 immunity in society.
- SARS-CoV-2, Antibody measurement, COVID-19, ELISA assay
How to Cite
References
Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif
M, et al. The first and second waves of the COVID-19 pandemic in
Africa: a cross-sectional study. The Lancet. 2021;397:1265-75.
Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection
of IgM and IgG antibodies in patients with coronavirus disease 2019.
Clinical & translational immunology. 2020;9:e1136.
Ralph R, Lew J, Zeng T, Francis M, Xue B, Roux M, et al. 2019-
nCoV (Wuhan virus), a novel Coronavirus: human-to-human
transmission, travel-related cases, and vaccine readiness. The Journal
of Infection in Developing Countries. 2020;14:3-17.
Xiao SY, Wu Y, Liu H. Evolving status of the 2019 novel
coronavirus infection: Proposal of conventional serologic assays for
disease diagnosis and infection monitoring. Journal of medical
virology. 2020;92:464.
Soori D. Waves and Peaks of COVID-19 in Iran. ISNA news agancy
Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, et al. Viral and
ANTIBODY KINETICS OF COVID-19 patients with different
disease severities in acute and convalescent phases: a 6-month followup study. Virologica Sinica. 2020;35:820-9.
Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y,
et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and
the path forward. American Association for the Advancement of
Science;2020.
GeurtsvanKessel CH, Okba NM, Igloi Z, Bogers S, Embregts CW,
Laksono BM, et al. An evaluation of COVID-19 serological assays
informs future diagnostics and exposure assessment. Nature
communications. 2020;11:1-5.
Zandi M, Nasimzade S, Pourhossein B, Fazeli M. A Snapshot of
Different Types Of Under Research Vaccines A Gainst Covid 1 9: A
Review. 2020.
Metcalf CJE, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J,
et al. Use of serological surveys to generate key insights into the
changing global landscape of infectious disease. The Lancet. 2016;
:728-30.
Hemati S. Antibodies testing, Immunity and immunity passport in
Covid-19. Laboratory & Diagnosis. 2020;12:8-22.
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests
for SARS-CoV-2. Jama. 2020;323:2249-51.
- Abstract Viewed: 20 times
- pdf Downloaded: 21 times
